Education
About Us
Working with TipRanks
Follow Us
Praxis Precision Medicines (PRAX)
NASDAQ:PRAX
PRAX Stock Chart & Stats
$325.11
-$2.82(-3.64%)
At close: 4:00 PM EST
$325.11
-$2.82(-3.64%)
Day’s Range― - ―
52-Week Range$26.70 - $356.00
Previous CloseN/A
Volume51.58K
Average Volume (3M)470.27K
Market Cap
$8.86B
Enterprise Value$6.59B
Total Cash (Recent Filing)$599.33M
Total Debt (Recent Filing)$110.00K
Price to Earnings (P/E)―
Beta2.06
Next Earnings
May 13, 2026EPS Estimate
-3.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.50
Shares Outstanding27,850,834
10 Day Avg. Volume428,402
30 Day Avg. Volume470,271
Financial Highlights & Ratios
PEG Ratio-0.68
Price to Book (P/B)7.55
Price to Sales (P/S)0.00
P/FCF Ratio-26.63
Enterprise Value/Market Cap0.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-34.74
Enterprise Value/Ebitda-21.02
Forecast
1Y Price Target
$612.94Price Target Upside88.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)-15.3
Revenue Forecast (FY)$4.46M
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyLate‑stage trials for ulixacaltamide met primary endpoints and the EMBOLD trial for relutrigine was stopped early for efficacy, indicating strong treatment effects that support approval prospects.
Financial RunwayA recent financing materially strengthened the cash position, enabling pre‑commercial activities and providing runway to support launch and development plans.
Scientific DifferentiationVormatrigine's targeted blockade of a specific sodium current and favorable interaction profile offer a clear biological rationale for seizure reduction and potential use alongside other antiseizure medications.
Bears Say
Program Timing RiskA delayed late‑stage readout for elsunersen increases uncertainty around program milestones and could postpone expected development progress.
Regulatory UncertaintyThe regulatory agency could raise concerns about the clinical data or company actions, which would threaten approval plans and introduce development delays.
Rising Operating CostsIncreased operating expense assumptions to support commercial preparedness elevate spending needs and act as a valuation headwind until product revenue emerges.
Praxis Precision Medicines News
PRAX FAQ
What was Praxis Precision Medicines’s price range in the past 12 months?
Praxis Precision Medicines lowest stock price was $26.70 and its highest was $356.00 in the past 12 months.
What is Praxis Precision Medicines’s market cap?
Praxis Precision Medicines’s market cap is $8.86B.
When is Praxis Precision Medicines’s upcoming earnings report date?
Praxis Precision Medicines’s upcoming earnings report date is May 13, 2026 which is in 69 days.
How were Praxis Precision Medicines’s earnings last quarter?
Praxis Precision Medicines released its earnings results on Feb 19, 2026. The company reported -$3.5 earnings per share for the quarter, missing the consensus estimate of -$3.126 by -$0.374.
Is Praxis Precision Medicines overvalued?
According to Wall Street analysts Praxis Precision Medicines’s price is currently Undervalued.
Does Praxis Precision Medicines pay dividends?
Praxis Precision Medicines does not currently pay dividends.
What is Praxis Precision Medicines’s EPS estimate?
Praxis Precision Medicines’s EPS estimate is -3.6.
How many shares outstanding does Praxis Precision Medicines have?
Praxis Precision Medicines has 27,850,834 shares outstanding.
What happened to Praxis Precision Medicines’s price movement after its last earnings report?
Praxis Precision Medicines reported an EPS of -$3.5 in its last earnings report, missing expectations of -$3.126. Following the earnings report the stock price went up 0.815%.
Which hedge fund is a major shareholder of Praxis Precision Medicines?
Currently, no hedge funds are holding shares in PRAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Praxis Precision Medicines Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$612.94 (88.53% Upside)
$612.94 (88.53% Upside)
Blogger Sentiment
Bullish
PRAX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 2.3%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
797.84%
12-Months-Change
Fundamentals
Return on Equity
-45.83%
Trailing 12-Months
Asset Growth
94.14%
Trailing 12-Months
Company Description
Praxis Precision Medicines
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
PRAX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized major clinical and regulatory progress (two NDAs filed, positive Phase III results, Breakthrough Therapy designation, multiple near-term readouts) and a strengthened balance sheet (pro forma ~$1.5B) enabling commercialization. Offsetting this are materially higher operating expenses (full-year OpEx +56% y/y), an anticipated further increase in 2026 to support launches, and commercial/payer timing uncertainties (including IRA considerations and label/titration questions). Overall, the highlights — substantial clinical validation, regulatory progress, clear launch planning, and strong cash runway — outweigh the lowlights related to cost increases and access timing risk.View all PRAX earnings summariesPRAX Stock 12 Month Forecast
Average Price Target
$612.94
▲(88.53% Upside)
Technical Analysis
ARS Pharmaceuticals
―
AbCellera Biologics
―
Zenas BioPharma, Inc.
―
Upstream Bio, Inc.
―
Septerna, Inc.
―
Ownership Overview
18.01% Insiders
16.65% Mutual Funds
2.01% Other Institutional Investors
51.25% Public Companies and Individual Investors